Question 1

Who are the top researchers at Synthon (Netherlands)?

Accepted Answer

Ranked on the quality score, Wim H.A. Dokter, Gijs F. M. Verheijden and Patrick H. Beusker lead among researchers whose main affiliation is Synthon (Netherlands).

Question 2

What are the most cited papers from Synthon (Netherlands)?

Accepted Answer

The most cited paper from Synthon (Netherlands) is "Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study" (Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al., 2019), with 577 citations. Next come "Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985" (225) and "The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers" (218).

Question 3

Which research topics does Synthon (Netherlands) publish most on?

Accepted Answer

By volume in 2022-now: Autism Spectrum Disorder Research, Child Abuse and Trauma, Immunotherapy and Immune Responses and Child and Adolescent Psychosocial and Emotional Development.

Question 4

Which keywords describe research at Synthon (Netherlands)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Chemotherapy, Monoclonal Antibody, Antibody Engineering, Fc Receptors and Breast Cancer.

Question 5

Which fields of science does Synthon (Netherlands) work in?

Accepted Answer

In all years, 37% of research at Synthon (Netherlands) is in Physical Sciences, 31% in Health Sciences. Its largest fields are Medicine (31%), Chemistry (21%), Biochemistry, Genetics and Molecular Biology (19%). It does 1.7× the world's share of Life Sciences.

Question 6

Is Synthon (Netherlands)'s research output growing?

Accepted Answer

Output in 2022-2025 was 31% lower than in 2018-2021.

Discussion